Tag Archives: Direct online Procurement

Policy Analysis and Guidance: Guangdong’s National Medical Product Review and Pricing Announcement

Guangdong Provincial Drug Exchange has announced the results of the national joint review and pricing for medical products in March 2025. This initiative aims to enhance transparency, ensure fair pricing, and support the efficient distribution of medical products.

Key Policy Highlights

Information Disclosure
- Purpose: To provide the public and medical institutions with accurate pricing information for newly listed medical products.
- Details: The announcement includes detailed pricing information for medical products that passed the review without objections during the display period.
Pricing Mechanism
- Negotiation: Products are included in the negotiated pricing procurement range, allowing medical institutions to purchase at prices not exceeding the listed prices.
- Efficiency: Streamlined processes ensure timely inclusion of products in the procurement range.
Post-Review Handling
- Information Verification: Products with pending information verification or incomplete registration certificates will be listed after verification is completed.
- Transparency: Ensuring all listed products meet regulatory standards and pricing requirements.

Policy Orientation and Industry Implications
The national joint review and pricing policy reflects Guangdong’s strategic focus on:

Transparency: Enhancing transparency in medical product pricing through public disclosure.
Fair Pricing: Ensuring medical institutions can access products at fair and reasonable prices.
Efficiency: Promoting efficient distribution and procurement processes to support healthcare delivery.

Conclusion
Guangdong’s approach to national medical product review and pricing sets a benchmark for regional medical product management, emphasizing transparency, fair pricing, and efficient distribution. Medical product enterprises should align with these guidelines to ensure smooth operations and contribute to healthcare efficiency.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1907745298520739840

Policy Analysis and Guidance: Yunnan’s Routine Medical Consumables Delisting Notification

Yunnan Province’s Government Procurement and Tendering Center has issued a notification regarding the delisting of certain medical consumables under the routine listing work for batch 20250305. This move aims to optimize the market by removing products that no longer meet the listing criteria, ensuring quality and supply stability.

Key Policy Highlights

Delisting Criteria
- Basis: Products are delisted based on enterprise applications and supporting documentation.
- Purpose: To maintain high standards for medical consumables and ensure market efficiency.
Product Details
- Example: The notification includes products like the “一次性使用麻醉呼吸管路组件” (Disposable Anesthesia Breathing Circuit Component) manufactured by Henan Tuoren Medical Device Group Co., Ltd.
Contact Information
- Support: Enterprises can contact the medical device procurement department for further inquiries.

Policy Orientation and Industry Implications
The delisting initiative reflects Yunnan’s strategic focus on:

Market Optimization: Removing underperforming or non-compliant products to enhance overall market quality.
Quality Assurance: Ensuring that only products meeting stringent standards remain available.
Transparency: Providing clear communication channels for enterprises regarding listing and delisting processes.

Conclusion
Yunnan’s approach to delisting medical consumables underscores its commitment to maintaining a high-quality and efficient market. This policy supports the reliability of the medical consumables supply chain and ensures healthcare providers have access to essential, quality-assured products. Enterprises should stay informed of these updates to maintain compliance and market access.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25153&CatalogId=3

Policy Analysis and Guidance: Kunming’s Third Batch of Provincial Alliance Drug Volume-Linked Procurement

Kunming City has announced the results of its third batch of provincial alliance drug volume-linked procurement, with the selected drugs scheduled to be available for trading online starting April 1, 2025. This initiative aims to optimize drug procurement processes, reduce costs, and ensure the availability of quality medications through a volume-linked procurement mechanism.

Key Policy Highlights

Online Trading Catalog
- Details: The selected drugs for Kunming’s third batch of provincial alliance volume-linked procurement are detailed in Attachment 1.
- Discontinuation: Previously selected drugs from the same manufacturer and formulation, as well as some products from the first batch of Kunming’s volume-linked procurement, will be discontinued after the new selected drugs are listed.
Implementation Timeline
- Effective Date: Medical institutions and insured retail pharmacies can procure the selected drugs through Yunnan Province’s Medical Security Information Platform starting April 1, 2025.
Sample Registration
- Filing Requirements: Drugs marked as “Requires Filing” in Attachment 1 must complete the basic drug notification and promise filing process.
- Process: Relevant enterprises should complete filing with the Yunnan Provincial Drug Administration as per the displayed announcement and establish distribution relationships in the procurement system.
Procurement and Distribution
- Direct or Entrusted Delivery: Selected drugs can be delivered directly by the selected manufacturer or entrusted to a pharmaceutical distribution company.
- Contract Signing: Medical institutions, manufacturers, and distributors must sign procurement contracts electronically in the procurement system starting now.
System Access
- Account Registration: Relevant enterprises should register for the procurement subsystem as per the 2024 notification.

Policy Orientation and Industry Implications
The implementation of Kunming’s third batch of volume-linked procurement reflects the city’s strategic focus on:

Cost Efficiency: Reducing drug prices through centralized procurement while maintaining quality standards.
Supply Stability: Ensuring the availability of essential medications through a reliable procurement mechanism.
Transparency: Promoting clear contractual agreements and accountability mechanisms.

Conclusion
Kunming’s volume-linked procurement framework sets a benchmark for regional drug management, emphasizing efficiency, quality, and accessibility. Stakeholders, including manufacturers, distributors, and healthcare providers, should align their operations with these guidelines to optimize compliance and patient outcomes.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25178&CatalogId=3